+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Idiopathic Pulmonary Fibrosis Market - Global Forecast 2026-2032- Product Image
Idiopathic Pulmonary Fibrosis Market - Global Forecast 2026-2032- Product Image
Sale

Idiopathic Pulmonary Fibrosis Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889780
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Idiopathic Pulmonary Fibrosis Market is projected to reach USD 3.45 Billion in 2026. It is expected to continue growing at a CAGR of 7.35%, reaching USD 5.31 Billion by 2032.

Idiopathic Pulmonary Fibrosis: Executive Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by irreversible scarring of lung tissue and declining respiratory function. Its clinical course is heterogeneous, and diagnosis can be difficult because symptoms such as exertional breathlessness and persistent cough overlap with other respiratory disorders. Management therefore depends on timely specialist assessment, multidisciplinary review, pulmonary function testing, high-resolution computed tomography, and, when appropriate, histopathological evaluation.
The care landscape increasingly emphasizes early recognition, antifibrotic treatment where clinically appropriate, symptom management, pulmonary rehabilitation, vaccination, oxygen support, and assessment for lung transplantation. Access remains influenced by diagnostic capacity, specialist availability, reimbursement, patient comorbidities, and differences in national clinical practice.

IPF Care Is Shifting Toward Earlier, Multidisciplinary Intervention

The landscape is moving from predominantly supportive management toward disease-modifying care combined with coordinated long-term monitoring. Greater awareness among primary-care and respiratory clinicians can shorten diagnostic delays, while multidisciplinary teams help distinguish IPF from connective-tissue-disease-associated and other fibrotic interstitial lung diseases.
Additional shifts include wider use of structured diagnostic pathways, remote monitoring, patient-reported outcomes, pulmonary rehabilitation, and supportive or palliative care integrated alongside active treatment. Clinical decisions increasingly account for functional status, frailty, oxygen needs, comorbid cardiovascular or gastrointestinal disease, and patient preferences rather than relying on a single measurement.

Artificial Intelligence Can Strengthen Detection, Stratification, and Monitoring

Artificial intelligence is being evaluated for pattern recognition in high-resolution chest imaging, identification of fibrotic features, and support for differential diagnosis. Properly validated tools could help prioritize suspicious scans, improve consistency between readers, and identify patients who may benefit from referral to specialist interstitial lung disease services.
AI may also assist with longitudinal analysis of pulmonary function, symptoms, imaging, and clinical records. However, deployment requires representative training data, external validation, transparent performance reporting, clinician oversight, privacy safeguards, and monitoring for bias. AI should support-not replace-multidisciplinary clinical judgment, especially when imaging findings are ambiguous or comorbid conditions complicate interpretation.

Regional Differences Reflect Diagnostic Capacity, Access, and Care Infrastructure

North America generally benefits from established specialist networks, advanced imaging, clinical research activity, and access to multidisciplinary care, although affordability, insurance coverage, rural access, and referral delays can remain important barriers. Europe has substantial clinical expertise and guideline infrastructure, but access to diagnostics, antifibrotic therapy, transplantation, and rehabilitation varies across countries and health systems.
Asia-Pacific combines highly developed respiratory services in some markets with major gaps in specialist capacity and diagnostic access elsewhere. Latin America faces uneven availability of high-resolution imaging, pathology, specialist consultation, and reimbursed treatment, with urban-rural disparities often pronounced. In the Middle East, investment in tertiary healthcare coexists with differences in referral pathways and workforce distribution. Africa commonly encounters limited specialist services, diagnostic infrastructure, oxygen availability, and disease registries, making awareness, referral networks, and scalable diagnostic approaches particularly important.

International Groups Show Uneven Policy Alignment and Health-System Readiness

ASEAN countries differ substantially in specialist workforce, reimbursement, imaging access, and availability of pulmonary rehabilitation, creating a need for adaptable regional referral and education models. BRICS members likewise span advanced tertiary centers and settings where diagnosis, registries, and long-term treatment access remain constrained. The European Union benefits from cross-border scientific collaboration and shared regulatory frameworks, while national reimbursement and service delivery continue to differ.
G7 health systems generally possess strong research and specialist capacity, but aging populations, healthcare costs, and unequal access still affect care pathways. GCC countries often have advanced tertiary facilities and increasing investment in respiratory care, alongside variation in national protocols and reliance on centralized services. NATO membership does not imply uniform IPF care; participating countries retain distinct health systems, epidemiology, reimbursement policies, and specialist availability.

Country-Level Priorities Range From Diagnostic Expansion to Coordinated Long-Term Care

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States have established respiratory expertise and specialist centers, while continuing to address referral delays, regional inequities, treatment affordability, and transplantation capacity. Japan and South Korea have sophisticated imaging and specialist services, with ongoing emphasis on aging-related disease burden, early recognition, and consistent access across regions. China and India face large and diverse patient populations, requiring expanded diagnostic capacity, trained clinicians, registries, and affordable long-term management.
Brazil and Mexico continue to encounter geographic and health-system differences affecting specialist access, diagnostic confirmation, and treatment continuity. Russia faces challenges linked to regional variation, specialist distribution, and access to advanced diagnostics and therapies. Across all listed countries, practical priorities include standardized diagnostic pathways, multidisciplinary review, reliable pulmonary function testing, oxygen access, rehabilitation, patient education, and integration of palliative care when appropriate.

Industry Leaders Should Focus on Earlier Diagnosis, Equitable Access, and Evidence Quality

Leaders should strengthen referral pathways between primary care, radiology, pulmonology, rheumatology, and transplant services; support education on progressive fibrotic lung disease; and develop care models that remain effective outside major urban centers. Partnerships with health systems should prioritize diagnostic quality, pulmonary rehabilitation, oxygen provision, adherence support, and patient-centered monitoring rather than treatment availability alone.
Evidence generation should reflect real-world diversity, including older adults, people with comorbidities, and patients from underrepresented regions. Digital and AI-enabled tools should be introduced through prospective validation, clear accountability, cybersecurity controls, and outcomes-based evaluation. Organizations should also support registries, transparent access programs, and health-economic analyses that help policymakers assess sustainable, equitable care.

Methodology Combines Clinical Evidence, Health-System Review, and Geographic Comparison

This executive summary uses a structured synthesis of established clinical concepts, publicly recognized diagnostic and management principles, and comparison of healthcare-system factors relevant to idiopathic pulmonary fibrosis. The assessment considers disease recognition, diagnostic pathways, multidisciplinary care, treatment access, rehabilitation, oxygen support, transplantation, patient experience, research activity, and digital-health readiness.
Regional, group, and country narratives are qualitative and comparative. They do not provide market estimates, market sizing, market shares, or forecasts. Findings should be interpreted alongside current clinical guidelines, local regulatory requirements, reimbursement policies, epidemiological surveillance, and institution-specific capabilities.

Better IPF Outcomes Depend on Coordinated, Evidence-Based Care

Idiopathic pulmonary fibrosis remains a serious progressive disease in which diagnostic delay and unequal access can materially affect patient experience and management options. The strongest opportunities lie in earlier specialist referral, consistent multidisciplinary assessment, appropriate disease-modifying treatment, proactive symptom and comorbidity management, and timely consideration of transplantation or palliative support.
Regional and country differences make adaptable implementation essential. Artificial intelligence and digital monitoring may improve efficiency and consistency, but only when grounded in rigorous validation and clinician-led care. Sustained progress will depend on collaboration among patients, clinicians, health systems, researchers, policymakers, and technology developers to make high-quality IPF care more timely, equitable, and patient-centered.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Idiopathic Pulmonary Fibrosis Market, by Drug Class
7.1. Introduction
7.2. Antifibrotic Agents
7.3. Tyrosine Kinase Inhibitors
7.4. Connective Tissue Growth Factor (CTGF) Inhibitors
7.5. Phosphodiesterase 4 (PDE4) Inhibitors
7.6. Integrin Inhibitors
7.7. Autotaxin Inhibitors
7.8. Lysophosphatidic Acid (LPA) Receptor Antagonists
7.9. Galectin-3 Inhibitors
8. Idiopathic Pulmonary Fibrosis Market, by Molecule Type
8.1. Introduction
8.2. Small Molecules
8.3. Monoclonal Antibodies
8.4. Recombinant Proteins
8.5. Peptides
8.6. Cell-Based Therapies
8.7. Gene-Based Therapies
9. Idiopathic Pulmonary Fibrosis Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Intravenous
9.4. Subcutaneous
9.5. Inhalation
10. Idiopathic Pulmonary Fibrosis Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Specialty Pulmonology Clinics
10.4. Academic And Research Institutes
10.5. Ambulatory Care Centers
11. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
11.4. Specialty Pharmacies
11.5. Online Pharmacies
12. Idiopathic Pulmonary Fibrosis Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Idiopathic Pulmonary Fibrosis Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Idiopathic Pulmonary Fibrosis Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Italy
14.12. Canada
14.13. Russia
14.14. Brazil
14.15. Mexico
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Algernon Pharmaceuticals Inc.
16.2. AnGes, Inc.
16.3. Avalyn Pharma, Inc.
16.4. BioAge Labs, Inc.
16.5. Blade Therapeutics, Inc.
16.6. Boehringer Ingelheim International GmbH
16.7. Bridge Biotherapeutics, Inc.
16.8. Bristol-Myers Squibb Company
16.9. Celon Pharma S.A.
16.10. Cidara Therapeutics, Inc.
16.11. Citius Pharmaceuticals, Inc.
16.12. Cumberland Emerging Technologies, Inc.
16.13. Cumberland Pharmaceuticals Inc.
16.14. Endeavor BioMedicines, Inc.
16.15. F. Hoffmann-La Roche Ltd
16.16. FibroGen, Inc.
16.17. Galecto Biotech AB
16.18. Insilico Medicine Hong Kong Limited
16.19. Kyorin Pharmaceutical Co., Ltd.
16.20. MediciNova, Inc.
16.21. Pliant Therapeutics, Inc.
16.22. PureTech Health plc
16.23. Trevi Therapeutics, Inc.
16.24. United Therapeutics Corporation
16.25. Vicore Pharma Holding AB
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Idiopathic Pulmonary Fibrosis Market, Years Considered for the Study
FIGURE 2. Global Idiopathic Pulmonary Fibrosis Market, Research Design
FIGURE 3. Global Idiopathic Pulmonary Fibrosis Market, Research Framework
FIGURE 4. Global Idiopathic Pulmonary Fibrosis Market, Data Triangulation
FIGURE 5. Global Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2025 vs 2032 (%)
FIGURE 9. Global Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Idiopathic Pulmonary Fibrosis Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Idiopathic Pulmonary Fibrosis Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Idiopathic Pulmonary Fibrosis Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Idiopathic Pulmonary Fibrosis Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Idiopathic Pulmonary Fibrosis Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Idiopathic Pulmonary Fibrosis Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Idiopathic Pulmonary Fibrosis Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Idiopathic Pulmonary Fibrosis Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Idiopathic Pulmonary Fibrosis Market Segmentation & Coverage
TABLE 2. Global Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 3. Global Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Antifibrotic Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antifibrotic Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antifibrotic Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Tyrosine Kinase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Tyrosine Kinase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Tyrosine Kinase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Connective Tissue Growth Factor (CTGF) Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Connective Tissue Growth Factor (CTGF) Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Connective Tissue Growth Factor (CTGF) Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Phosphodiesterase 4 (PDE4) Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Phosphodiesterase 4 (PDE4) Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Phosphodiesterase 4 (PDE4) Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Integrin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Autotaxin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Autotaxin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Autotaxin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Lysophosphatidic Acid (LPA) Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Lysophosphatidic Acid (LPA) Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Lysophosphatidic Acid (LPA) Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Galectin-3 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Galectin-3 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Galectin-3 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 29. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Recombinant Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Recombinant Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Recombinant Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Cell-Based Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Cell-Based Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Cell-Based Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Gene-Based Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Gene-Based Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Gene-Based Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 48. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Specialty Pulmonology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Specialty Pulmonology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Specialty Pulmonology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Specialty Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Specialty Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Specialty Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Europe Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Europe Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 95. Europe Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 96. Europe Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 97. Europe Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Europe Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. North America Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. North America Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 101. North America Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 102. North America Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. North America Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. North America Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. Latin America Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Latin America Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 107. Latin America Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 108. Latin America Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. Latin America Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Latin America Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. Africa Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Africa Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 113. Africa Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 114. Africa Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. Africa Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Africa Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Middle East Idiopathic Pulmonary Fibrosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Middle East Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 119. Middle East Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 120. Middle East Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. Middle East Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Middle East Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. Global Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. NATO Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. NATO Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 126. NATO Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 127. NATO Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. NATO Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. NATO Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. G7 Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. G7 Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 132. G7 Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 133. G7 Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. G7 Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. G7 Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. BRICS Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. BRICS Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 138. BRICS Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 139. BRICS Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 140. BRICS Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. BRICS Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. European Union Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. European Union Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 144. European Union Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 145. European Union Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. European Union Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. European Union Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. ASEAN Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. ASEAN Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 150. ASEAN Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 151. ASEAN Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. ASEAN Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. ASEAN Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. GCC Idiopathic Pulmonary Fibrosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. GCC Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 156. GCC Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 157. GCC Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. GCC Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. GCC Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Global Idiopathic Pulmonary Fibrosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. China Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 162. China Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 163. China Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 164. China Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 165. China Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. China Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. United States Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 168. United States Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 169. United States Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 170. United States Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. United States Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. United States Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. Japan Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 174. Japan Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 175. Japan Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 176. Japan Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. Japan Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Japan Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. India Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 180. India Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 181. India Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 182. India Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. India Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. India Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. Germany Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 186. Germany Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 187. Germany Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 188. Germany Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. Germany Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Germany Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. United Kingdom Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 192. United Kingdom Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 193. United Kingdom Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 194. United Kingdom Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. United Kingdom Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. United Kingdom Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Australia Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 198. Australia Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 199. Australia Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 200. Australia Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. Australia Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Australia Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. France Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 204. France Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 205. France Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 206. France Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. France Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. France Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. South Korea Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 210. South Korea Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 211. South Korea Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 212. South Korea Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. South Korea Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. South Korea Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. Italy Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 216. Italy Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 217. Italy Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 218. Italy Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 219. Italy Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Italy Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. Canada Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 222. Canada Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 223. Canada Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 224. Canada Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 225. Canada Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. Canada Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. Russia Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 228. Russia Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 229. Russia Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 230. Russia Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. Russia Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Russia Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. Brazil Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 234. Brazil Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 235. Brazil Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 236. Brazil Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 237. Brazil Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. Brazil Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Mexico Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 240. Mexico Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 241. Mexico Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 242. Mexico Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. Mexico Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Mexico Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. Spain Idiopathic Pulmonary Fibrosis Market Size, 2017-2032 (USD Million)
TABLE 246. Spain Idiopathic Pulmonary Fibrosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 247. Spain Idiopathic Pulmonary Fibrosis Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 248. Spain Idiopathic Pulmonary Fibrosis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 249. Spain Idiopathic Pulmonary Fibrosis Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. Spain Idiopathic Pulmonary Fibrosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Global Idiopathic Pulmonary Fibrosis Market Share, by Key Player, 2025
TABLE 252. Global Idiopathic Pulmonary Fibrosis Market, Key Experts

Companies Mentioned

  • Algernon Pharmaceuticals Inc.
  • AnGes, Inc.
  • Avalyn Pharma, Inc.
  • BioAge Labs, Inc.
  • Blade Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bridge Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Celon Pharma S.A.
  • Cidara Therapeutics, Inc.
  • Citius Pharmaceuticals, Inc.
  • Cumberland Emerging Technologies, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Endeavor BioMedicines, Inc.
  • F. Hoffmann-La Roche Ltd
  • FibroGen, Inc.
  • Galecto Biotech AB
  • Insilico Medicine Hong Kong Limited
  • Kyorin Pharmaceutical Co., Ltd.
  • MediciNova, Inc.
  • Pliant Therapeutics, Inc.
  • PureTech Health plc
  • Trevi Therapeutics, Inc.
  • United Therapeutics Corporation
  • Vicore Pharma Holding AB

Related Topics

Related Reports

Idiopathic Pulmonary Fibrosis - Global Strategic Business Report - Product Image

Idiopathic Pulmonary Fibrosis - Global Strategic Business Report

  • Report
  • 202 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Market Report 2026 - Product Image

Idiopathic Pulmonary Fibrosis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Market by Therapy; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035 - Product Image

Idiopathic Pulmonary Fibrosis Market by Therapy; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

  • Report
  • 187 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Treatment Market - Product Image

Idiopathic Pulmonary Fibrosis Treatment Market

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.